Skip to the page

Data / Drug companies / Biocon Pharma Inc.

Biocon Pharma Inc.: 90 products in the FDA NDC directory, labeler code 70377

Biocon Pharma Inc. (labeler code 70377) lists 90 products in the FDA National Drug Code Directory, covering 32 finished drugs by generic name. By type: 90 prescription drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on September 25, 2026.

SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.

Labeler code
70377
Products in commercial distribution
90
Packages
194
Finished drugs by generic name
32
Prescription products
90
Over the counter products
0
Flagged as original packager
57 of 57 products that carry the flag
Started marketing in the last 12 months
15
Earliest marketing start
December 17, 2015
openFDA record search
api.fda.gov

Products by marketing category

Share of the company's products in commercial distribution.

Marketing categoryProductsShare
Generic drugs (ANDA)90100%

Products by type

TypeProductsShare
Prescription drugs90100%

Drugs it lists

Finished drugs by generic name, with how many companies list each.

Dosage forms

Dosage formProductsShare
Tablet, film coated3437.8%
Tablet1718.9%
Capsule1718.9%
Tablet, delayed release55.6%
Suspension33.3%
Injection, powder, lyophilized, for solution33.3%
Tablet, for suspension33.3%
Capsule, delayed release22.2%
Injection, solution11.1%
Solution11.1%
Powder, for suspension11.1%
Tablet, film coated, extended release11.1%

Pharmacologic classes

FDA established pharmacologic classes of its products.

Newest products

By marketing start date.

ProductProduct NDCDosage formMarketing categoryMarketing start
Deflazacort Oral Suspension70377-188SuspensionGeneric drugs (ANDA)September 25, 2026
Eltrombopag70377-186Tablet, film coatedGeneric drugs (ANDA)September 9, 2026
Eltrombopag70377-185Tablet, film coatedGeneric drugs (ANDA)September 9, 2026
Eltrombopag70377-184Tablet, film coatedGeneric drugs (ANDA)September 9, 2026
Eltrombopag70377-183Tablet, film coatedGeneric drugs (ANDA)September 9, 2026
Tofacitinib XR70377-057Tablet, film coated, extended releaseGeneric drugs (ANDA)June 3, 2026
Dapagliflozin70377-024Tablet, film coatedGeneric drugs (ANDA)May 1, 2026
Dapagliflozin70377-023Tablet, film coatedGeneric drugs (ANDA)May 1, 2026
Liraglutide70377-094InjectionGeneric drugs (ANDA)April 25, 2026
Liraglutide70377-095Injection, solutionGeneric drugs (ANDA)March 27, 2026
Sertraline HCl70377-129CapsuleGeneric drugs (ANDA)January 30, 2026
Sertraline HCl70377-128CapsuleGeneric drugs (ANDA)January 30, 2026
Everolimus70377-092Tablet, for suspensionGeneric drugs (ANDA)January 14, 2026
Everolimus70377-091Tablet, for suspensionGeneric drugs (ANDA)January 14, 2026
Everolimus70377-090Tablet, for suspensionGeneric drugs (ANDA)January 14, 2026
Sacubitril and Valsartan70377-033Tablet, film coatedGeneric drugs (ANDA)July 17, 2025
Sacubitril and Valsartan70377-032Tablet, film coatedGeneric drugs (ANDA)July 17, 2025
Sacubitril and Valsartan70377-031Tablet, film coatedGeneric drugs (ANDA)July 17, 2025
Norepinephrine bitartrate70377-121Injection, solution, concentrateGeneric drugs (ANDA)July 1, 2025
Everolimus70377-112TabletGeneric drugs (ANDA)June 2, 2025
Everolimus70377-071TabletGeneric drugs (ANDA)June 2, 2025
Everolimus70377-070TabletGeneric drugs (ANDA)June 2, 2025
Everolimus70377-069TabletGeneric drugs (ANDA)June 2, 2025
Micafungin70377-076Injection, powder, lyophilized, for solutionGeneric drugs (ANDA)June 1, 2025
Micafungin70377-075Injection, powder, lyophilized, for solutionGeneric drugs (ANDA)June 1, 2025

Updated November 6, 2026. Read from US Food and Drug Administration, National Drug Code Directory (openFDA). CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.